TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sana Biotechnology ( (SANA) ) has issued an update.
On August 28, 2025, Mary Agnes Wilderotter announced her resignation from Sana Biotechnology‘s Board of Directors, effective August 29, 2025. Her departure, which includes stepping down from her roles as Chairperson of the Nominating and Corporate Governance Committee and a member of the Audit Committee, is not due to any disagreements with the company’s operations or policies.
The most recent analyst rating on (SANA) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Sana Biotechnology stock, see the SANA Stock Forecast page.
Spark’s Take on SANA Stock
According to Spark, TipRanks’ AI Analyst, SANA is a Underperform.
Sana Biotechnology’s overall stock score is primarily impacted by significant financial challenges, including consistent losses and a lack of revenue. Despite some improvements in balance sheet stability and operating cash flow, the bearish technical indicators and negative valuation metrics underscore the need for strategic changes to achieve growth and profitability.
To see Spark’s full report on SANA stock, click here.
More about Sana Biotechnology
Sana Biotechnology operates in the biotechnology industry, focusing on developing advanced therapies using engineered cells as medicines to treat a variety of diseases.
Average Trading Volume: 5,650,542
Technical Sentiment Signal: Sell
Current Market Cap: $778.7M
For a thorough assessment of SANA stock, go to TipRanks’ Stock Analysis page.